Daniel Fremed, MD
Vascular Surgery · Springfield, NJNPI 1548536436
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,422 of the $21,641 with a category attached, or 62.0%. 29 manufacturers reported payments, led by Inari Medical, Inc. at 25.4% of the total. Reporting peaked in 2024 at $7,446 and has fallen 79.2% since, to $1,546 in 2025.
Across 245 payments — averaging $88.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$6K
- Penumbra, Inc.$4K
- Medtronic$2K
- W. L. Gore & Associates, Inc.$2K
- Endologix LLC$1K
- Cardiovascular Systems Inc.$1K
- plus $6K from 23 others
What the payments were for
- Consulting fees$6423%
- Speaking & faculty fees$6,85032%
- Travel & lodging$7273%
- Food & beverage$13,42262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 19 | $5,503 |
| Penumbra, Inc. | 41 | $4,369 |
| Medtronic(2 entities) | 39 | $2,021 |
| W. L. Gore & Associates, Inc. | 28 | $1,752 |
| Endologix LLC | 9 | $1,124 |
| Cardiovascular Systems Inc. | 14 | $1,009 |
| Silk Road Medical, Inc. | 7 | $919 |
| Bard Peripheral Vascular, Inc. | 12 | $802 |
| Cook Medical LLC | 8 | $632 |
| BD | 1 | $517 |
| Boston Scientific | 8 | $383 |
| Lemaitre Vascular, Inc. | 15 | $378 |
| Limflow Inc. | 2 | $312 |
| Bolton Medical Inc | 3 | $308 |
| Stryker | 6 | $218 |
| Angiodynamics, Inc. | 3 | $204 |
| Acera Surgical, Inc. | 3 | $203 |
| Smith+Nephew | 2 | $192 |
| Tactile Systems Technology Inc | 3 | $177 |
| Abbott | 2 | $89 |
| KCI USA, Inc. | 1 | $84 |
| Convatec Inc. | 1 | $78 |
| Pfizer | 5 | $76 |
| Cvrx, Inc. | 1 | $75 |
| Johnson & Johnson | 5 | $74 |
| Lantheus Medical Imaging, Inc. | 3 | $69 |
| Integra Lifesciences Corporation | 2 | $32 |
| Solventum Corporation | 1 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$4,752
- CT THROMBECTOMY SYSTEM KIT$4,752
- Indigo System$2,180
- RUBY Coil$1,342
- ENROUTE Transcarotid Neuroprotection System$827
- ENROUTE Transcarotid Stent System$827
- ENHANCE Transcarotid Peripheral Access Kit$827
- ENROUTE 0.014 Guidewire$827
- Product in Development$575
- Diamondback Peripheral$549
- HawkOne$528
- VIABAHN VBX Balloon Expandable Endoprosthesis$514
- Alto Abdominal Stent Graft System$433
- FlowTriever$414
- ClotTriever$414
- Torus Stent Graft System$331
- ENDOCROSS Device$331
- GORE VIABAHN VBX Balloon Expandable Endo$326
- ENDURANT IIS$292
- Ovation$251
How this compares
$21,641 in reported general payments places this provider in the 80th percentile of 182 vascular surgery providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 14 | $18,280 |
| EliquisApixaban | 16 | $12,753 |
| ClopidogrelClopidogrel Bisulfate | 42 | $509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $74 | $18,28014 claims |
| PfizerEliquis | $76 | $12,75316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 vascular surgery providers in New Jersey.
Other vascular surgery in Springfield
- Michael AddisSpringfield$16K
- Jonathan LeeSpringfield$12K
- Steven EliasEnglewood$509K
- Michael WildermanHackensack$383K
- David O'ConnorHackensack$272K
- Joseph LombardiPomona$266K
- William BeckermanNew Brunswick$176K
- Neil PoulsenRockaway$148K
- Massimo NapolitanoWayne$147K
- Laurel HastingsCamden$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.